PRESS RELEASE
For immediate release

Ticker Symbol: CUR

DIAGNOCURE ANNOUNCES FISCAL 2006 THIRD QUARTER RESULTS

QUEBEC CITY (September 11, 2006) – DiagnoCure Inc. (TSX: CUR), a leading developer and provider of innovative high-value cell-based assays and molecular diagnostics for the detection of cancers, today announced its financial results for the third quarter ended July 31, 2006.

Results for the Third Quarter of Fiscal 2006

Total revenues for the third quarter of 2006 were $1,302,485 compared with $1,683,283 for the third quarter of 2005. The Gen-Probe PCA3 prostate cancer assay is now being sold in the US in its ASR format. Two laboratories announced in May 2006 the commercial availability of PCA3 assay. Given the recent release of the assay, there is not yet any developed sales pattern for the new test so it is difficult to predict what any future royalty revenue flow will accrue to DiagnoCure. However, as was anticipated, DiagnoCure did receive a modest first royalty payment from Gen-Probe PCA3 sales made during the latter part of Gen-Probes second quarter, which ended on June 30, 2006. In accordance with the terms of the arrangement with Gen-Probe, now that their PCA3 test is commercially available, DiagnoCure withdrew its uPM3™ test from the market in June 2006. Income from research & development contracts, predominantly with Gen-Probe, has decreased in the third quarter of 2006 by a net amount of $184,429 as was anticipated under the contract terms.

Sales of DiagnoCure's bladder cancer test, ImmunoCyt™ / uCyt+™ were $81,789 for the third quarter of 2006 versus $103,881 for the same period a year ago. While uCyt+™ sales outside the U.S. have increased by 8% over last year, US based sales of ImmunoCyt™ have suffered from strong competition and reimbursement issues. The sales of the subsidiary Samba Technologies SAS, after inter-company elimination of Samba work done for DiagnoCure, were $148,014 for the third quarter of 2006 compared to $285,359 a year ago.

Cost of sales decreased $67,663 from $323,333 for the third quarter of 2005 to $255,670 for the third quarter of 2006. This decrease is related to lower actual product sales. Operating expenses rose from $2,244,149 for the third quarter of 2005 to $2,660,833 for the same period in 2006, for an increase of $416,684 primarily as a result of increased research & development spending in line with the R & D program and to an increase in administrative expenses.

Based on the above, for the third quarter of 2006, DiagnoCure recorded a net loss of $1,614,018 or $0.04 per share, compared with $884,199, or $0.03 per share, for the third quarter of 2005. These results are in line with management expectations and reflect our continuing R&D commitments.

At the end of the quarter, cash, short-term investments and long-term investments stood at $20,214,024, down $2,507,681 from the $22,721,705 reported as at October 31, 2005. That represents an average monthly cash burn of only $278,632 for the first three quarters. Management is satisfied that it has adequate cash resources to execute its business plan in the near-term and mid-term.

Highlights of the Quarter

On March 16, 2006, Pierre Désy, President and Chief Executive Officer of the Company, announced his intention to retire in the coming fiscal year. On August 1, 2006, Mr. Paul Gobeil, Chairman of the Board of DiagnoCure, announced the appointment of Mr. John C. Schafer to the position of President and Chief Executive Office of DiagnoCure Inc. to take effect on August 23, 2006. Mr. Schafer has also been appointed as a member of the DiagnoCure Board of Directors effective September 11, 2006.

Mr. Schafer brings to DiagnoCure more than 30 years experience in the field of diagnostics, along with an excellent track record in management and growth of high technology diagnostics companies. He has the credentials, the knowledge and the demonstrated ability to realize our significant potential in prostate cancer diagnostics and to broaden our base in the field of diagnostics with emerging technologies.

As a consequence of the exclusive partnership with Gen-Probe and their use of the PCA3 technology in the diagnosis of prostate cancer, 2006 is a year of great importance. After the transfer of the PCA3 technology to their APTIMA®

platform, Gen-Probe has successfully completed the development of the PCA3 prostate cancer test in a quantitative format, as a second-generation detection test from the PCA3 gene and in May 2006, two laboratories, Bostwick Laboratories and AmeriPath, in conjunction with Molecular Profiling Institute, announced the commercial availability of the PCA3 assay in the ASR format based on Gen-Probe's technology. Gen-Probe further confirmed in July that they have advanced discussions with larger US reference labs and potential "second phase partners" for further PCA3 distribution in the United States and Canada.

During the month of July 2006, *The Urology Times*, the leading news source for urologists, published an article citing recent AUA presentations where five independent studies on the new PCA3 assay as an aid to critical diagnostic decisions in prostate cancer were reported. In conjunction with a June 2006 *Clinical Chemistry* article about PCA3, several posters at recent international urologic conferences and a successfully sponsored symposium at the EAU meeting in Paris, have considerably increased the visibility of PCA3 from a scientific point of view.

Gen-Probe has reiterated publicly that the European launch of PCA3 remains on track to introduce a full CE-marked product for commercial sale by this year-end. Seven sites across Europe have already signed on to participate in the EU PCA3 Performance Evaluations.

PCA3 remains the cornerstone of Gen-Probe's and DiagnoCure's oncology efforts. It is characterized as the most specific prostate cancer marker yet discovered and given the major unmet medical needs due to the limitations of the PSA test and the estimated 10 million men with negative prostate biopsies in the US, PCA3 presents Gen-Probe and DiagnoCure with a significant commercial opportunity.

On May 30, 2006, DiagnoCure and Gen-Probe jointly announced that they have amended and expanded the terms of their license and collaboration agreement to include additional work on the PCA3 gene and a research contract on lung cancer markers that Gen-Probe acquired from Corixa.

Financial Data

For the periods of	Three-months ended July 31		Nine-months ended July 31	
	2006	2005	**2006**	2005
Sales	**304,345**	537,922	**1,248,753**	1,820,923
Revenue under research and license agreement	**790,175**	974,604	**2,406,878**	3,013,931
Interest	**207,965**	170,757	**591,647**	591,993
Total revenues	**1,302,485**	1,683,283	**4,247,278**	5,426,847
Cost of sales	**255,670**	323,333	**928,091**	1,252,157
Gross margin	**1,046,815**	1,359,950	**3,319,187**	4,174,690
Operating expenses*	**2,660,833**	2,244,149	**8,298,105**	6,293,355
Net loss *	**(1,614,018)**	(884,199)	**(4,978,918)**	(2,118,665)
Diluted net loss per share	**(0.04)**	(0.03)	**(0.14)**	(0.07)
Weighted average number of common shares outstanding	**34,424,258**	34,242,048	**34,385,170**	34,208,933
**Includes non-cash expense adjustment for stock-based compensation*	***284,806***	*334,245*	***833,290***	*935,499*

Consolidated Balance Sheets

	As at July 31	
	2006	2005
Cash, cash equivalents, temporary and long-term investments	**20,214,024**	24,003,261
Total assets	**23,274,624**	27,126,416
Shareholders' equity	**21,312,643**	25,831,697

About DiagnoCure

DiagnoCure specializes in the development, production and commercialization of diagnostic tests for the detection of cancers. DiagnoCure's first product, ImmunoCyt™ /uCyt+™, is an important tool for the diagnosis and monitoring of bladder cancer. In 2003, the Company completed the development of uPM3™, a non-invasive test for the early detection of prostate cancer, and granted an exclusive worldwide license for the use of the PCA3 technology in prostate cancer diagnosis to Gen-Probe (NASDAQ: GPRO). After successfully completing a lung cancer pilot study on bronchial aspirates, and having secured rights to other molecular markers in lung cancer from Genzyme and Gen-Probe, DiagnoCure is now exploring additional applications for lung cancer detection using other testing media such as blood, sputum, or biopsy materials. Additional information can be found at www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypothesis and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contact: DiagnoCure Inc.
Thom Skinner
Chief Financial Officer
(418) 527-6100 e-mail: communications@diagnocure.com